News Sep 17, 2026
Porton Congratulates Partner Acepodia on FDA Clearance of IND Application for ACE723, a Dual-Payload ADC
This project demonstrates Porton's process-development and scale-up capabilities for complex conjugates and adds to its experience supporting innovative biopharma companies worldwide.
News Sep 15, 2026
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
This successful recertification highlights the standardized operation of the site's management systems, the rigor of its on-site management, and the robustness of its risk control mechanisms, further validating the continued effectiveness of the dual systems.
News Sep 01, 2026
Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026
CPHI creates connections and inspires partnerships across the global pharma community, championing innovation at the heart of pharma through in-person and online events that grant access to endless opportunities.
NewslettersAug 31, 2026
Porton Newsletter - August 2026 Recap
Porton Newsletter - August 2026 Recap
News Aug 05, 2026
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.
NewslettersJul 31, 2026
Porton Newsletter - July 2026 Recap
Porton Newsletter - July 2026 Recap
News Jul 08, 2026
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
News Jul 03, 2026
Porton Delivers Dual-Payload ADC IND, Advancing Next-generation Conjugate Drug Development
Porton One-stop Biologics and Conjugates CDMO Platform successfully completed the full-cycle delivery of process development and GMP IND clinical sample manufacturing for a dual-payload ADC.
News Jul 02, 2026
Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR's 30th Anniversary
Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR’s 30th Anniversary
